By Katherine Hamilton
Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients.
The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.
Shares rose 8% to $1.85 in premarket trading Monday.
The drug combination is designed to treat people with recurrent or metastatic head and neck squamous cell carcinoma. Combining the therapies has increased response rates by sevenfold and more than doubled median overall survival compared with historical results. The treatment has no new safety signals, Immutep said.
Immutep has requested a meeting with the Food and Drug Administration to discuss next steps including paths to approval. The company is continuing patient follow-ups, data collection and analysis, and plans to provide a further update later this year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 05, 2025 09:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。